EP Patent

EP1509232A1 — A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Assigned to H Lundbeck AS · Expires 2005-03-02 · 21y expired

What this patent protects

A pharmaceutical composition comprising (a) an effective amount of one or more of acetylcholinesterase inhibitor(s) or a pharmaceutically effective salt thereof and (b) an effective amount of one or more NMDA-antagonist(s).

USPTO Abstract

A pharmaceutical composition comprising (a) an effective amount of one or more of acetylcholinesterase inhibitor(s) or a pharmaceutically effective salt thereof and (b) an effective amount of one or more NMDA-antagonist(s).

Drugs covered by this patent

donepezil-hydrochloride (DONEPEZIL HYDROCHLORIDE)

Patent Metadata

Patent number: EP1509232A1
Jurisdiction: EP
Classification: —
Expires: 2005-03-02
Drug substance claim: No
Drug product claim: No
Assignee: H Lundbeck AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.